Table 1. Clinical characteristics and electrocardiographic data.
| CA with preserved EF | Survivors | Non-survivors | P value | |
| n = 41 | n = 22 | n = 19 | ||
| Age (years) | 65±9 | 65±8 | 65±11 | 0.825 |
| Male (n; %) | 61% | 59% | 63% | 0.790 |
| BMI (kg/m2) | 24±3 | 23±2 | 24±4 | 0.355 |
| Systolic blood pressure (mmHg) | 119±19 | 122±17 | 116±21 | 0.354 |
| Diastolic blood pressure (mmHg) | 72±13 | 75±12 | 69±14 | 0.203 |
| Heart rate (beats/min) | 76±9 | 75±12 | 77±9 | 0.419 |
| NYHA class | 2.3±0.8 | 2.1±0.8 | 2.4±0.8 | 0.195 |
| NYHA class III/IV, n (%) | 44 | 33% | 55% | 0.162 |
| Pleural effusion (%) | 43% | 37% | 50% | 0.419 |
| Number of non-cardiac organs involved | 1.5±0.9 | 1.2±0.8 | 1.8±0.8 | 0.017 |
| Renal (%) | 59% | 45% | 74% | 0.069 |
| Hepatic/gastrointestinal (%) | 69% | 65% | 74% | 0.557 |
| Lung (%) | 8% | 0% | 16% | 0.106 |
| Neuropathic (%) | 5% | 5% | 5% | 1.000 |
| Soft tissues/bone (%) | 10% | 5% | 16% | 0.342 |
| Biomarkers | ||||
| NT-proBNP (pg/mL) | 3813 (1546–14564) | 1830 (998–21882) | 4543 (2846–15193) | 0.352 |
| Creatinine (mg/mL) | 1.2 (0.8–1.8) | 1.1 (0.7–1.9) | 1.2 (0.9–1.8) | 0.845 |
| GGT (UL) | 91 (32–221) | 74 (36–226) | 111 (29–242) | 0.684 |
| AKP (UL) | 83 (67–141) | 73 (62–95) | 90 (68–216) | 0.125 |
| Albumin (g/dL) | 3.7 (3.0–4.1) | 3.7(3.4–4.0) | 3.6 (2.8–4.3) | 0.756 |
| Free Kappa light chain (mg/L) | 21 (6–114) | 21 (17–129) | 16 (1.5–114) | 0.384 |
| Free Lambda light chain (mg/L) | 22 (10–122) | 12 (9–122) | 31 (21–327) | 0.082 |
| Kappa/Lambda ratio | 1.11 (0.07–8.40) | 1.43 (0.327–12.70) | 0.45 (0.01–7.84) | 0.343 |
| Cardiac-related drug therapy | ||||
| Beta blocker | 43% | 50% | 35% | 0.368 |
| Angiotensin converting enzyme inhibitor | 38% | 45% | 29% | 0.330 |
| Diuretics | 62% | 50% | 77% | 0.098 |
| Electrocardiography | ||||
| Unexplained low voltage | 50% | 50% | 50% | 1.000 |
| QRS-T wave pseudo-infarct changes | 44% | 45% | 42% | 0.855 |
| I/II° atrioventricular block | 64% | 53% | 75% | 0.188 |
| Left/right bundle branch block | 39% | 50% | 26% | 0.129 |
Non-survivors vs. survivors P<0.05 indicated significantly different. CA: cardiac amyloidosis; BMI: body mass index; NYHA class: New York Heart Association functional classification; NT-proBNP: N-terminal pro-B-type natriuretic peptide; GGT: Gamma-glutamyl transpeptidase; AKP: alkaline phosphatase enzyme.